Lung Cancer
Coverage from the ASCO20 Virtual Scientific Program

Focus on Lung Cancer


Featured Content

New! Chemo/immunotherapy Combo Promising for Treatment of Mesothelioma

Inoperable malignant pleural mesothelioma is a rare and aggressive cancer of the protective lining of the lungs, or pleura, often caused by exposure to asbestos. At the annual meeting of the ASCO 2020 Annual Meeting, held virtually May 29-31, a researcher from the Johns Hopkins Kimmel Cancer Center presented findings from a multicenter study that evaluated the efficacy of an immunotherapy/ chemotherapy combination for the disease (Abstract 9003).

Read Now

Pembrolizumab + Chemo Continues to Improve Efficacy in Metastatic Nonsquamous NSCLC

With longer follow-up, pembrolizumab plus chemotherapy continued to improve efficacy outcomes in previously untreated metastatic nonsquamous non-small cell lung cancer (NSCLC) over placebo and chemotherapy, with a manageable toxicity profile, according to findings presented at the ASCO 2020 Annual Meeting (Abstract 9582).

Read Now

Immunotherapy Combo Plus Chemo Improves Survival in First-Line NSCLC

Findings from the phase III CheckMate-9LA trial demonstrated that nivolumab plus ipilimumab, given concomitantly with 2 cycles of chemotherapy, had a statistically significant and clinically meaningful survival benefit as a first-line treatment of metastatic non-small cell lung cancer (NSCLC).

Read Now

First-Line Tiragolumab + Atezolizumab Improves Survival Among NSCLC Patients

Findings suggest that the anti-TIGIT antibody tiragolumab, when combined with atezolizumab, had a clinically meaningful improvement in overall response rate (ORR) and progression-free survival (PFS) compared to placebo plus atezolizumab for the first-line treatment of non-small cell lung cancer (NSCLC).

Read Now

Pembrolizumab Plus Chemo Improves Survival in Extensive-Stage Small-Cell Lung Cancer

First-line pembrolizumab plus etoposide significantly improved progression-free survival (PFS) and prolonged overall survival (OS) among patients with extensive-stage small cell lung cancer (ES-SCLC) when compared to placebo plus etoposide, according to data presented during an oral presentation at the ASCO 2020 Annual Meeting (Abstract 9001).

Read Now

Adjuvant Osimertinib Delays Recurrence in Localized NSCLC

Data from a phase III study demonstrated that treatment with osimertinib following surgery for localized non-small cell lung cancer (NSCLC) with an EGFR mutation significantly improved disease-free survival (DFS). The findings were presented at the ASCO 2020 Annual Meeting (Abstract LBA5).

Read Now

Loading